Drug Profile
TQ F3083
Alternative Names: TQ-F3083Latest Information Update: 23 Aug 2022
Price :
$50
*
At a glance
- Originator Centaurus Biopharma; Chia Tai Tianqing Pharmaceutical Group
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 26 Jul 2022 NCT03986073/700308458 - NDR: incorporated QC feedback
- 26 Jul 2022 No development reported - Phase-II for Type 2 diabetes mellitus in China (PO) (NCT03986073)
- 01 Jan 2020 Phase-II clinical trials in Type 2 diabetes mellitus in China (PO) (NCT03986073)